MA30266B1 - Utilisation de deferiprone et methodes de traitement prophylactique et/ou therapeutique de la maladie de friedreich resultant d'un dysfonctionnement du traitement intracellulaire du fer - Google Patents

Utilisation de deferiprone et methodes de traitement prophylactique et/ou therapeutique de la maladie de friedreich resultant d'un dysfonctionnement du traitement intracellulaire du fer

Info

Publication number
MA30266B1
MA30266B1 MA31216A MA31216A MA30266B1 MA 30266 B1 MA30266 B1 MA 30266B1 MA 31216 A MA31216 A MA 31216A MA 31216 A MA31216 A MA 31216A MA 30266 B1 MA30266 B1 MA 30266B1
Authority
MA
Morocco
Prior art keywords
treatment
iron
deferiprone
dysfunction
intracellular
Prior art date
Application number
MA31216A
Other languages
English (en)
Inventor
Arnold Munnich
Michael Spino
Ioav Cabantchik
Original Assignee
Arnold Munnich
Michael Spino
Ioav Cabantchik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arnold Munnich, Michael Spino, Ioav Cabantchik filed Critical Arnold Munnich
Publication of MA30266B1 publication Critical patent/MA30266B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une quantité thérapeutiquement active de défériprone ou de déférasirox ou de sels de qualité physiologique desdits composés pour la prévention, la stabilisation, le traitement ou la guérison d'une maladie de Friedreich induite par le fer chez des patients, ladite maladie résultant de dégâts aux mitochondries induits par le fer, et le but de ladite quantité thérapeutiquement active étant préférentiellement de réduire les réserves de fer des mitochondries. La présente invention concerne également le traitement d'autres états pathologiques affectant le cerveau lorsque l'un des éléments clés de l'apparition de la pathologie est un dysfonctionnement du traitement intracellulaire du fer.
MA31216A 2006-02-22 2008-09-08 Utilisation de deferiprone et methodes de traitement prophylactique et/ou therapeutique de la maladie de friedreich resultant d'un dysfonctionnement du traitement intracellulaire du fer MA30266B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22

Publications (1)

Publication Number Publication Date
MA30266B1 true MA30266B1 (fr) 2009-03-02

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31216A MA30266B1 (fr) 2006-02-22 2008-09-08 Utilisation de deferiprone et methodes de traitement prophylactique et/ou therapeutique de la maladie de friedreich resultant d'un dysfonctionnement du traitement intracellulaire du fer

Country Status (24)

Country Link
US (3) US20070197649A1 (fr)
EP (1) EP1991225B1 (fr)
JP (1) JP5730466B2 (fr)
KR (1) KR20080104329A (fr)
CN (1) CN101420954A (fr)
AU (1) AU2007219009B2 (fr)
BR (1) BRPI0708211A2 (fr)
CA (1) CA2642778A1 (fr)
DK (1) DK1991225T3 (fr)
ES (1) ES2441065T3 (fr)
IL (1) IL193598A (fr)
MA (1) MA30266B1 (fr)
MX (1) MX2008010824A (fr)
MY (1) MY151412A (fr)
NZ (1) NZ570730A (fr)
PL (1) PL1991225T3 (fr)
PT (1) PT1991225E (fr)
RS (1) RS53225B (fr)
RU (1) RU2008137604A (fr)
SG (1) SG170020A1 (fr)
SI (1) SI1991225T1 (fr)
TN (1) TNSN08338A1 (fr)
UA (1) UA95099C2 (fr)
WO (1) WO2007095728A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
CN102964296B (zh) 2007-03-28 2015-03-25 阿普泰克斯科技公司 去铁酮的氟化衍生物
AU2008355464C1 (en) * 2008-04-25 2014-11-20 Chiesi Farmaceutici S.P.A. Liquid formulation for deferiprone with palatable taste
MA33090B1 (fr) 2009-01-26 2012-03-01 Michael Spino Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer
PT2448922E (pt) 2009-07-03 2014-12-02 Apotex Technologies Inc Derivados fluorados de 3-hidroxipiridina-4-onas
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
CA2809747C (fr) * 2010-08-30 2018-05-01 Roberto Testi Compositions et methodes pour traiter l'ataxie de friedreich avec l'interferon gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (fr) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition destinée à être utilisée dans le traitement de maladies neurodégénératives ayant des syndromes parkinsoniens
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
MD3684344T2 (ro) 2017-10-25 2025-09-30 Chiesi Farm Spa Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
WO2025006917A1 (fr) * 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisations de chélateurs du fer pour le traitement du bégaiement

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (fr) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derives de la quinone pour le traitement ou la prevention de maladies associees a une surcharge en fer
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (fr) * 2000-06-30 2011-09-13 Apotex Inc. Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа

Also Published As

Publication number Publication date
EP1991225A4 (fr) 2009-07-29
MX2008010824A (es) 2009-06-08
US20090023784A1 (en) 2009-01-22
DK1991225T3 (da) 2013-12-16
JP2009527506A (ja) 2009-07-30
CN101420954A (zh) 2009-04-29
US20070197649A1 (en) 2007-08-23
AU2007219009A1 (en) 2007-08-30
IL193598A0 (en) 2009-08-03
RU2008137604A (ru) 2010-03-27
NZ570730A (en) 2013-05-31
SI1991225T1 (sl) 2014-02-28
PL1991225T3 (pl) 2014-04-30
WO2007095728A1 (fr) 2007-08-30
AU2007219009B2 (en) 2012-12-20
EP1991225A1 (fr) 2008-11-19
IL193598A (en) 2012-08-30
TNSN08338A1 (en) 2009-12-29
BRPI0708211A2 (pt) 2011-05-17
CA2642778A1 (fr) 2007-08-30
SG170020A1 (en) 2011-04-29
JP5730466B2 (ja) 2015-06-10
US20130190365A1 (en) 2013-07-25
EP1991225B1 (fr) 2013-11-06
PT1991225E (pt) 2014-02-13
RS53225B (sr) 2014-08-29
MY151412A (en) 2014-05-30
ES2441065T3 (es) 2014-01-31
KR20080104329A (ko) 2008-12-02
UA95099C2 (ru) 2011-07-11

Similar Documents

Publication Publication Date Title
MA30266B1 (fr) Utilisation de deferiprone et methodes de traitement prophylactique et/ou therapeutique de la maladie de friedreich resultant d'un dysfonctionnement du traitement intracellulaire du fer
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
EA200701370A1 (ru) Способы получения стерильных суспензий или лиофилизатов труднорастворимых комплексов основных пептидов (варианты), стерильная суспензия и лиофилизат вышеназванных комплексов, фармацевтическая композиция, набор и лекарственное средство на их основе
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
WO2009137217A8 (fr) Régénération et enrichissement thérapeutiques de la lubrification de la surface oculaire
EA200601494A1 (ru) Имидазольные соединения для лечения нейродегенеративных расстройств
EA200400135A1 (ru) Применение производных амидинов для лечения амилоидоза
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
RU2007125589A (ru) Способ улучшения структуры и/или функций артериол, активный агент для улучшения структуры и/или функций артериол и набор для лечения состояний, характеризующихся ненормальной структурой или функцией артериол
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
MA32299B1 (fr) Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone
CA2534634A1 (fr) Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
MA33804B1 (fr) Composition pharmaceutique pour le traitement des brûlures cutanées